Hypertension and nephrology - 2018;22(01)

Content

Journal Special issues Previous issue Next number Archives

Hypertension and nephrology

FEBRUARY 20, 2018

[A Letter to Our Readers]

ALFÖLDI Sándor, KÉKES Ede

PDF| Summary Cite COPYRIGHT FEES

HUN

2018;22(01)

Hypertension and nephrology

FEBRUARY 20, 2018

[Press Release of the Hungarian Society of Hypertension Concerning the New American Hypertension Limit – the Hungarian Limit Remains 140/90 mmHg Still!]

PDF| Summary Cite COPYRIGHT FEES

HUN

2018;22(01)

Hypertension and nephrology

FEBRUARY 20, 2018

[Experience with mycophenolate mofetil containing immunosuppressive regimen in de novo kidney transplant recipients (ORANGE study).]

WAGNER László, KALMÁR-NAGY Károly, TORONYI Éva, TÖRÖK Szilárd, PATONAI Attila, SZAKÁLY Péter

[Mycophenolate mofetil (MMF) has been used as an immunosuppressive agent in renal transplant recipients for more than two decades. The aim of the ORANGE study was to collect data with respect to the efficacy and safety of MMF containing immunosuppressive regimens during standard nephrology care in Hungarian clinical centres. Efficacy of the therapy was primarily evaluated via moni - toring of renal function based on glomerular filtration rate (GFR) values calculated on the basis of the MDRD-175... tovább »

PDF| Summary Cite COPYRIGHT FEES

HUN

2018;22(01)

Hypertension and nephrology

FEBRUARY 20, 2018

[Therapy of pathological phosphate metabolism in chronic kidney disease]

LADÁNYI Erzsébet, DEÁK György, TISLÉR András, SZABÓ András

[The Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline update for Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD) was published in the summer of 2017 and has become a very important guidance of the complex therapy of patients with CKD. It is well known that, besides infections, cardiovascular diseases in close causal relationship with CKD-MBD are leading mortality factors of patients with CKD. Therefore the publication of the new international guideline is... tovább »

PDF| Summary Cite COPYRIGHT FEES

HUN

2018;22(01)

Hypertension and nephrology

FEBRUARY 20, 2018

[How the recognition and treatment of primary aldosteronism could be improved?]

BAJNOK László

[Practically there were no randomized, controlled trials in the area of PA so far, but recently two such ones have appeared. In addition, both are paradigm- forming; yet not built into (yet?) the expert opinions. In the field of primary aldosteronism (PA), there is a sharp contrast between the world’s leading experts in many areas. There is consensus in respect that hypokalaemia, therapy resistance and vascular complications are more common in PA than in primary hypertension. According to... tovább »

PDF| Summary Cite COPYRIGHT FEES

HUN

2018;22(01)

Hypertension and nephrology

FEBRUARY 20, 2018